Skip to main content

Update to Age Requirement for Prior Authorization of Inotuzumab Ozogamicin (Besponsa) Effective July 1, 2024

Last updated on

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.

Effective for dates of service on or after July 1, 2024, the age requirement for prior authorization of inotuzumab ozogamicin (Besponsa) (procedure code J9229) will be expanded to include pediatric and adult clients who are one year of age or older.

Refer to the current Texas Medicaid Provider Procedures Manual, Outpatient Drug Services Handbook, subsection 6.67.1, “Prior Authorization Requirements for Inotuzumab ozogamicin (Besponsa),” for additional prior authorization criteria.

For more information, call the TMHP Contact Center at 800-925-9126.